When it Comes to First Launches, Can Two Heads Be Better Than One?

Posted by Andy Singley on Thu, Mar 05, 2020

Judith Kulich, Ben Hohn and Cody Powers contributed to this blog post.

In recent years, we have seen an uptick in the number of “first launches”—defined by ZS as a company’s first marketed asset with FDA “novel” status. While earlier in the decade we saw just a handful of first launches each year, over the past three years we’ve seen the rate of first launches roughly double that. More pre-commercial companies are choosing to take their assets all the way to market compared to earlier in the decade.


>
Read More

Accelerating Market Access: Three Trends Shaping Pharma’s Future

Posted by Ed Schoonveld on Mon, Jan 06, 2020

Dean Hakanson co-wrote this blog post with Ed Schoonveld. This blog post was originally published on The Price of Global Health.

Is the demand for value-based care merely superficial? Are the industry’s decision-making and incentive systems built to encourage clinical innovation? How will pharma companies rethink their pipelines to improve poor commercialization efforts?


>
Read More

Innovation Is Healthcare’s New Normal

Posted by Pratap Khedkar on Fri, Aug 02, 2019

Sometimes it’s hard to keep in mind that healthcare was once considered a stodgy, conservative industry—at least by outsiders. Advances in care development and delivery happened, but the healthcare experience was generally the same as it had been decades before, as were the business models leveraged across the healthcare landscape. We’d grown, maybe not comfortable with, but accepting of the status quo.


>
Read More

How the Right RWE Platform Serves Up the Ingredients for Innovation

Posted by ZS Editors on Tue, Sep 04, 2018

Many pharmaceutical companies have realized the benefits of moving from standalone real-world data (RWD) projects to full-fledged, cross-functional real-world evidence (RWE) capabilities to drive everything from their R&D programs to their commercial teams’ efforts to demonstrate value—and technology is central to their success. “Real-world evidence is essentially extracting intelligence out of real-world data, and now that we have the right technology, scalable cloud storage and tremendous processing power, we’re actually able to sift through big data to find those insights,” says Abhay Jha, a principal at ZS and the business technology lead in the firm’s R&D excellence practice.  


>
Read More

Better Decisions, Faster: Forecasting in Times of Change

Posted by Matt Wills on Fri, May 11, 2018

This post is the first in a four-part series on how pharmaceutical companies can elevate their forecasting operations.

Effective forecasts should inform many decisions, from earnings guidance to brand-level investment prioritization. To do that effectively, forecasters should be a strategic partner to the broader organization by supporting investment decisions and risk management. Achieving that partnership requires a forecasting organization that’s objective and data-driven, comprehensive and consistent across the portfolio and globally, constantly adapting to a changing healthcare and technology landscape, and focused on enabling real-time organizational decision-making and risk management.


>
Read More